EN DE
Watch BRIM Biotechnology, Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

BRIM Biotechnology, Inc. (6885) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of BRIM Biotechnology, Inc. stock TWD 7.79, price TWD 27.50, that is 71.7% below the price, quality 39 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW

BB BRIM Biotechnology, Inc. logo Thin data Nov 6, 2026

BRIM Biotechnology, Inc.

6885 · TW
Very expensive, weak quality

Our calculation puts a fair price 72% below what the stock costs today.

Low debt
Mixed Growth (revenue 3y +118.5 %/yr in TWD)
Fair value 7.79 TWD · Strongly overvalued
Quality 39/100
Negative free cash flow
Trails peers (2/7)
Narrow moat 9/100
Thin data
Watch BRIM Biotechnology, Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

90.50 TWD 20.05 TWD Fair Value 7.79 TWD Jun 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

53‑month range 20.05 TWD – 90.50 TWD · fair‑value band 5.14 TWD – 9.73 TWD · the 27.50 TWD price screens above the 7.79 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow BRIM Biotechnology in your weekly email

Every Wednesday you see whether BRIM Biotechnology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BRIM Biotechnology, Inc. engages in the research and development of drugs and therapies to combat and cure diseases in Taiwan. The company's lead product candidate is BRM421, a neurotrophic peptide which has completed a Phase 3 clinical trial for the treatment of dry eye disease.

Show moreShow less

It is also developing BRM424, a treatment option that has completed Phase 1 clinical trial for neurotrophic keratitis; BRM411, a dual target inhibitor, which has completed Phase 2 clinical trial for the treatment of glaucoma; BRM412, an anti-angiogenic eye drop that has completed Phase 2 clinical trial to treat wet age-related macular degeneration; and BRM521, a PEDF-derived short peptide that is in pre-clinical trial to relieve and repair tissue damage caused by osteoarthritis.

BRIM Biotechnology, Inc. was founded in 2013 and is based in Taipei, Taiwan.

Stock analysis

BRIM Biotechnology, Inc. (6885) currently trades at 27.50 TWD, while our model-based Fair Value estimate is 7.79 TWD, 72% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 88/100, which puts the data coverage at low.

Scenario range: 5.14 TWD (bear) to 9.73 TWD (bull), the price of 27.50 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

BRIM Biotechnology, Inc. reported revenue of 5.5M TWD in FY2025 versus 360K TWD in FY2021, a compound +97.6%/yr. Reported net income was −436M TWD in FY2025.

Key figures

Market cap 3.7B TWD (≈ $111M) Micro · EPS (TTM) −3.26 TWD · Return on equity −26.5% · Return on assets (EBIT) −24.0% (5-year average) · Operating margin −2,165% · Revenue (TTM) 10.6M TWD · Revenue growth (YoY) +152% · Free cash flow −654M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 18% below its 52-week high and 35% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −72%, 6885 screens richer than that median.

Fair Value models

Bear 5.14 TWD Fair Value 7.79 TWD Bull 9.73 TWD
Price 27.50 TWD · Downside -71.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 5.14 TWD 7.79 TWD 9.73 TWD 55
All 1 models by family
Asset-Based
NCAV (Graham) 5.14 TWD 7.79 TWD 9.73 TWD 55

Open the full fair value analysis →

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 70
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 64
How calm the share price moves, does not count
Price momentum 62
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 38
Distance to the 52-week high, does not count
New shares 58
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1,548.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+118.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−25,893.1% (2021) → −8,250.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6885 screens overvalued: fair value 72% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare BRIM Biotechnology, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 557 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 39 · Below median
Fair Value upside −71.7% · Below median
Profitability
Return on assets −23.9% · Below median
Growth and dividend
Revenue growth (quarter YoY) 151.7% · Top 25%
Balance sheet
Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.21× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 21

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $919.96 $1,275 +39% vs 6885
Samsung Biologics Co 207940 1,510,000 KRW 1,661,000 KRW +10% vs 6885
Vertex Pharmaceuticals Incorporated VRTX $550.87 $601.80 +9% vs 6885
WuXi Biologics (Cayman) Inc 2269 HK$48.92 HK$52.38 +7% vs 6885
Genmab A/S GMAB kr 3,661 kr 3,880 +6% vs 6885
argenx SE ARGX $962.27 $908.40 −6% vs 6885
CSL Limited CSL A$200.73 A$181.40 −10% vs 6885
BeOne Medicines AG 6160 HK$248.20 HK$152.80 −38% vs 6885
Celltrion, Inc 068270 210,000 KRW 74,945 KRW −64% vs 6885
Royalty Pharma plc RPRX $68.77 $19.01 −72% vs 6885

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BRIM Biotechnology, Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "BRIM Biotechnology, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/6885

Frequently asked questions

Is BRIM Biotechnology, Inc. (6885) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of 7.79 TWD versus a price of 27.50 TWD, about 72% lower (overvalued).
What is the fair value of 6885?
Our model-based fair value for BRIM Biotechnology, Inc. is 7.79 TWD (as of Nov 6, 2026), built from audited fundamentals. The current price: 27.50 TWD.
What is the quality score of 6885?
BRIM Biotechnology, Inc. has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BRIM Biotechnology, Inc. (6885)?
Our model-based price target is the fair value of 7.79 TWD (as of Nov 6, 2026) from 1 valuation models. Cautious scenario 5.14 TWD, optimistic scenario 9.73 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the BRIM Biotechnology, Inc. stock forecast for 2026?
Our models put fair value at 7.79 TWD, about 72% lower versus a price of 27.50 TWD (overvalued). Cautious scenario 5.14 TWD, optimistic scenario 9.73 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of BRIM Biotechnology, Inc. (6885)?
BRIM Biotechnology, Inc. reported trailing-twelve-month revenue of about 10.6M TWD (latest available figure, as of Nov 6, 2026).
What is the intrinsic value of BRIM Biotechnology, Inc. (6885)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BRIM Biotechnology, Inc. it is 7.79 TWD per share (as of Nov 6, 2026), against a price of 27.50 TWD. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is BRIM Biotechnology, Inc. stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 6885 trades above its calculated fair value: price 27.50 TWD, fair value 7.79 TWD, a gap of about −72% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6885?
No. The price is what the market pays today (27.50 TWD); the fair value is what the company's own numbers justify (7.79 TWD). For BRIM Biotechnology, Inc. the two are 19.71 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is BRIM Biotechnology, Inc. worth?
The market values BRIM Biotechnology, Inc. at about 3.7B TWD (market capitalisation, as of Nov 6, 2026). Per share that is 27.50 TWD; our models calculate a fair value of 7.79 TWD per share.
What do the bullish and bearish scenarios say about 6885?
Our models span a range for BRIM Biotechnology, Inc.: cautious scenario 5.14 TWD, base 7.79 TWD, optimistic 9.73 TWD per share (as of Nov 6, 2026, price 27.50 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BRIM Biotechnology, Inc. (6885)?
Balance-sheet figures for BRIM Biotechnology, Inc. (as of Nov 6, 2026): return on equity −26.5%, debt of 0.00 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is 6885 from its 52-week high?
BRIM Biotechnology, Inc. trades at 27.50 TWD, about 18% below its 52-week high of 33.60 TWD and 35% above the low of 20.30 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 7.79 TWD is for.
Which stocks are comparable to BRIM Biotechnology, Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BRIM Biotechnology, Inc. stock attractive at the current price?
The data as of Nov 6, 2026: price 27.50 TWD, calculated fair value 7.79 TWD (−72%), Quality Score 39/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6885 calculated?
We run BRIM Biotechnology, Inc. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 7.79 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. BRIM Biotechnology, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BRIM Biotechnology, Inc. (6885)?
The closing price on Nov 9, 2026 was 27.50 TWD. Our model-based fair value is 7.79 TWD, about 72% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BRIM Biotechnology, Inc. right now?
The price sits above even our optimistic bull case (9.73 TWD). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (5.14 TWD to 9.73 TWD) leaves room in how you read the outcome.

Key figures of BRIM Biotechnology, Inc.

How large is the market capitalisation of BRIM Biotechnology, Inc. (6885)?
The market capitalisation of BRIM Biotechnology, Inc. is 3.7B TWD (≈ $111M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of BRIM Biotechnology, Inc. (6885)?
Earnings per share at BRIM Biotechnology, Inc. are −3.26 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of BRIM Biotechnology, Inc. (6885)?
The return on equity (ROE) of BRIM Biotechnology, Inc. is −26.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BRIM Biotechnology, Inc. (6885)?
On an EBIT basis the return on assets of BRIM Biotechnology, Inc. is −24.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BRIM Biotechnology, Inc. (6885)?
The operating margin of BRIM Biotechnology, Inc. is −2,165% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BRIM Biotechnology, Inc. (6885)?
Revenue at BRIM Biotechnology, Inc. is growing +152% versus a year earlier (3y avg +119%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does BRIM Biotechnology, Inc. (6885) generate?
The free cash flow of BRIM Biotechnology, Inc. is −654M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch BRIM Biotechnology, Inc. in the live analysis

One click puts BRIM Biotechnology, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.